(Q51090690)

http://europepmc.org/abstract/MED/28329763

29 March 2018

title

The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. (English)

1 reference

http://europepmc.org/abstract/MED/28329763

29 March 2018

1 reference

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Andrew A Wylie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Joseph Schoepfer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Wolfgang Jahnke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sandra W Cowan-Jacob

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alice Loo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Pascal Furet

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Andreas L Marzinzik

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Xavier Pelle

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jerry Donovan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Wenjing Zhu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Silvia Buonamici

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

A Quamrul Hassan

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Franco Lombardo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Varsha Iyer

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Michael Palmer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Giuliano Berellini

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Stephanie Dodd

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sanjeev Thohan

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Hans Bitter

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

David M Ross

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Timothy P Hughes

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lilli Petruzzelli

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

K Gary Vanasse

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Markus Warmuth

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Francesco Hofmann

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Nicholas J Keen

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

William R Sellers

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

22 March 2017

1 reference

http://europepmc.org/abstract/MED/28329763

29 March 2018

published in

Nature

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

543

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

733-737

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

7647

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28329763%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nature21702

2 June 2020

exact match

0 references

cites work

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

A myristoyl/phosphotyrosine switch regulates c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Structural basis for the autoinhibition of c-Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

21 January 2018

DNA replication fidelity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Evolutionary dynamics of cancer in response to targeted combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE21702